Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Francesco DE COBELLI

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4014-3711; OpenAlex author ID A5022352601, A5125975734. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 5 papers

Papers 18

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  3. Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-026-09467-z↗
  4. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  5. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  6. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  7. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  8. Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Co-author DOI 10.1016/j.ejso.2023.02.005↗
  9. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  10. Limited impact of discretization/interpolation parameters on the predictive power of CT radiomic features in a surgical cohort of pancreatic cancer patients. Co-author DOI 10.1007/s11547-023-01649-y↗
  11. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15143704↗
  12. The impact of nutritional status on pancreatic cancer therapy. Co-author DOI 10.1080/14737140.2022.2026771↗
  13. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control stud… Co-author DOI 10.4103/eus-d-21-00200↗
  14. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… Co-author DOI 10.3390/cancers13184512↗
  15. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Last author DOI 10.3390/cancers13194938↗
  16. Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Co-author DOI 10.1055/a-1221-9879↗
  17. Preoperative sarcopenia determinants in pancreatic cancer patients. Co-author DOI 10.1016/j.clnu.2016.10.014↗
  18. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Co-author DOI 10.1002/bjs.10063↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 16 shared papers, 2020–2026 · strength 2.74
  2. Diego Palumbo · 11 shared papers, 2021–2026 · strength 2.07
  3. Michele Reni · 11 shared papers, 2020–2026 · strength 1.73
  4. Stefano Crippa · 9 shared papers, 2021–2026 · strength 1.67
  5. Nicolò Pecorelli · 9 shared papers, 2016–2026 · strength 1.59
  6. Giulio Belfiori · 7 shared papers, 2021–2026 · strength 1.31
  7. Giulia Gasparini · 6 shared papers, 2024–2026 · strength 1.25
  8. Marco Schiavo Lena · 6 shared papers, 2023–2026 · strength 1.20
  9. Domenico Tamburrino · 6 shared papers, 2021–2026 · strength 1.17
  10. Stefano Partelli · 5 shared papers, 2024–2026 · strength 1.06
  11. Gabriele Capurso · 7 shared papers, 2020–2026 · strength 0.96
  12. Paolo Giorgio Arcidiacono · 7 shared papers, 2020–2026 · strength 0.96
  13. Federico De Stefano · 4 shared papers, 2025–2026 · strength 0.87
  14. Paolo Riccardo Camisa · 3 shared papers, 2025–2026 · strength 0.67
  15. Giuseppe Malleo · 3 shared papers, 2026 · strength 0.65
  16. Gabriella Lionetto Lionetto · 3 shared papers, 2026 · strength 0.65
  17. Roberto Salvia · 3 shared papers, 2026 · strength 0.65
  18. Sabrina Gloria Giulia Testoni · 5 shared papers, 2020–2023 · strength 0.62
  19. Maria Chiara Petrone · 5 shared papers, 2020–2023 · strength 0.62
  20. Marina Macchini · 3 shared papers, 2022–2026 · strength 0.59
  21. Gianpaolo Balzano · 4 shared papers, 2016–2026 · strength 0.50
  22. Emanuel Della‐Torre · 4 shared papers, 2020–2023 · strength 0.48
  23. Gemma Rossi · 4 shared papers, 2020–2023 · strength 0.47
  24. Fabio Casciani · 2 shared papers, 2026 · strength 0.46
  25. Claudio Luchini · 2 shared papers, 2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.